CN102008496B - Medicament for treating breast cancer and preparation method thereof - Google Patents
Medicament for treating breast cancer and preparation method thereof Download PDFInfo
- Publication number
- CN102008496B CN102008496B CN 201010563758 CN201010563758A CN102008496B CN 102008496 B CN102008496 B CN 102008496B CN 201010563758 CN201010563758 CN 201010563758 CN 201010563758 A CN201010563758 A CN 201010563758A CN 102008496 B CN102008496 B CN 102008496B
- Authority
- CN
- China
- Prior art keywords
- active ingredient
- medicament
- medicine
- oxygen
- medicinal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a medicament for treating breast cancer and a preparation method thereof. The medicament comprises a preparation which is prepared from 3-beta-oxygen-alpha-L-arabinofuranosyl-based-28-norepinephrine ursolic-12, 17-diene serving as a medicinal active ingredient and medicinal auxiliary materials. The medicament comprises 1 to 90 weight percent of the medicinal active ingredient and 10 to 99 weight percent of the medicinal auxiliary materials. The medicinal active ingredient has a structural formula shown in the specification. The preparation method for the medicament for treating the breast cancer comprises the following steps of: (1) crushing sanguisorba carbon serving as a medicinal raw material; extracting and filtering repeatedly; and concentrating filtrate to obtain a liquid extract; (2) dispersing the liquid extract obtained in the step (1) with water; extracting the dispersed liquid extract with chloroform; and recovering a solvent from extract liquid under normal pressure or a reduced pressure to obtain an extract; (3) performing silica column chromatography separation on the extract obtained in the step (2); performing recrystallization on solid obtained by suction filtering to obtain the medicinal active ingredient of a compound; and (4) preparing the preparation by using 20 to 90 weight percent of the medicinal active ingredient and the balance of the medicinal auxiliary materials. The medicament is used for treating the breast cancer, has a good treatment effect, and can replace oral Western medicament in a postoperative chemotherapy period.
Description
Technical field
The present invention relates to medicine, is a kind of medicine of treating breast carcinoma and preparation method thereof.
Background technology
Breast carcinoma is a kind of sickness rate disease with high, and according to the preliminary statistics, nearly 10 annual morbidities are ascendant trend gradually.The method of treatment breast carcinoma is medicine and operation at present; Most patients needs operative treatment; Chemotherapy is a kind of Therapeutic Method preferably after the ocal resection, and no matter Drug therapy still is the medicine that postoperative chemotherapy was taken in the phase, and effectively medicine generally is Western medicine; Yet the side effect of Western medicine proves very tangible through clinical.Though the Chinese medicine of treatment breast carcinoma is arranged in the disclosed data,, there are not data to show that it is evident in efficacy as yet.Therefore, in order to reduce the toxic and side effects that the patient with breast cancer takes Western medicine, this area is little in continuous research toxic and side effects always for many years, and the medicine of treatment breast carcinoma evident in efficacy is in the hope of reducing the dose of Western medicine.
Summary of the invention
The purpose of this invention is to provide a kind of medicine of treating breast carcinoma and preparation method thereof, it is used to treat breast carcinoma, makes its therapeutic effect good, and alternative operation back chemotherapy Western medicine for oral use in the phase.
The present invention is for realizing above-mentioned purpose, and realize through following technical scheme: a kind of medicine of treating breast carcinoma comprises that the medicine active ingredient is: 3
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12, the medicament that 17-diene and pharmaceutic adjuvant are processed, medicine active ingredient by weight percentage is that 1%-90%, pharmaceutic adjuvant are 10%-99%, 3
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12, the structural formula of 17-diene is:
Said pharmaceutical formulation is a tablet, and the medicine active ingredient of tablet is that 20%-70%, pharmaceutic adjuvant are 30%-80%.
Said pharmaceutical formulation is a capsule, and capsular medicine active ingredient is that 20%-90%, pharmaceutic adjuvant are 10%-80%.
Said pharmaceutical formulation is aqueous injection or freeze dried powder, and the medicine active ingredient is that 1%-5%, pharmaceutic adjuvant are 95%-99%.
Said pharmaceutical formulation is powder or granule, and medicine active ingredient 10%-20%, pharmaceutic adjuvant are 80%-90%.
A kind of method for preparing of treating the medicine of breast carcinoma of the present invention may further comprise the steps:
1. get charred Radix Sanguisorbae and pulverize the back and be medicine material, add the methanol or the ethanol of ten times of amounts of raw material, or aqueous alcohols, room temperature or be heated to 60 ℃-90 ℃ extracted 1-24 hours, repeated to extract 1-3 times, filtered, and filtrating is the concentrated fluid extract that obtains under normal pressure or decompression;
2. with step 1. in fluid extract with 5-10 times of weight aqueous dispersion, with amount of water 1/3 volumes of acetic acid ethyl ester extraction, but re-extract 5-8 time, with extract normal pressure or decompression and solvent recovery, must extractum;
3. step extractum is 2. carried out column chromatography for separation, adopt chloroform-methanol system gradient elution, the 90:10 eluting is partly merged, obtain chemical compound 3 through Sephedax-LH 20 gel filtration chromatography separation and purification again through thin layer chromatography
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12, the 17-diene;
4. get 3 by weight percentage
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 1%-90%, pharmaceutic adjuvant 10%-99% process medicament according to the conventional method for preparing of medicament.
The structural formula of medicine active ingredient of the present invention, providing quasi-molecular ion peak m/z with high-resolution fast atom bombardment mass spectrometry is 541.3891 [M+H]+(C
34H
53O
5, value of calculation: 541.3888), confirm that its molecular formula is C34H52O5.Infrared spectrum (potassium bromide) cm-1:3421 (OH), 2938 (saturated C-H), 1450,1388 (CH3), 1065 (C-O).Proton nmr spectra shows 5 unimodal signal δ 0.91 of methyl (H-26), 0.94 (H-25), 0.94 (H-27), 1.05 (H-24); 1.07 (H-23) with 2 methyl bimodal signal 0.85 (H-29,3H, d; J=6.1Hz), 0.96 (H-30,3H; D, J=5.9Hz), pointing out this chemical compound is pentacyclic triterpenoid.Also show one even the hydrogen signal δ 3.30 on the oxygen carbon (H-12,1H, dd, J=11.6,4.4Hz) with an alkene hydrogen signal δ 5.68 (H-12, m).(1H, d are the terminal hydrogen signal of arabinose J=2.0Hz) to δ 5.59, and other proton signal is at 4.2 ~ 5.0ppm on the sugar.Nuclear magnetic resonance, NMR charcoal spectrum shows 4 olefinic carbon characteristic signal δ 117.4 (C-12); δ 128.9 (C-17); δ 133.5 (C-18) and 137.6 (C-13) and sugared outside 3 oxygen carbon signal δ of company 87.3 of low field displacement because of being connected also have 5 company's oxygen carbon signals of sugar.The concrete numerical value of 13C-NMR is seen table 1.
Nuclear magnetic resonance, NMR charcoal spectrum shows the signal after δ 87.3 is for the displacement of aglycon C-3 generation glycosidation; Infer that chemical compound has sugar to be connected on 3 oxygen of aglycon; It is relevant that the relevant spectrum of heteronuclear multiple bond (HMBC spectrum) shows that arabinose terminal hydrogen (δ 5.59) and aglycon C-3 (δ 87.3) have, and explains that arabinose is connected 3 of aglycon.The glycosidic bond configuration of sugar contrasts according to the coupling constant of terminal hydrogen and with data in literature, confirms as а-L configuration respectively.
Make the C of chemical compound, H ownership be able to confirm that concrete numerical value sees the following form through the relevant spectrum of heteronuclear multiple bond (HMBC spectrum), heteronuclear Multiple-Quantum Coherences spectrum (HMQC spectrum).So confirm the structure of this chemical compound, promptly 3
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12, the 17-diene.
(solvent is dimethyl sulfoxide-d to the nuclear magnetic resonance, NMR charcoal spectrum of table 1 chemical compound
6) and undistorted polarization transfer enhancing spectrum (DEPT spectrum) data
Medicine active ingredient of the present invention derives from charred Radix Sanguisorbae, and charred Radix Sanguisorbae has blood coagulation anastalsis preferably, holds back the skin ulcer effect.The applicant discovers, 3 in the charred Radix Sanguisorbae
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12, the 17-diene has the effect of significant its growth of inhibition to breast tumor cell, and can also suppress the formation of breast tumor new vessels, thereby for treating breast carcinoma fabulous basis is provided.
Experiment shows 3
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12, the 17-diene has significant pharmacological action.
1, antitumor
The active ingredient of medicine of the present invention is a ursane type pentacyclic triterpene glycosides compound, and ursolic acid (ursolic acid) is the representative composition of this compounds.Ursolic acid is a broad-spectrum antitumoral compounds, external to the toxic effect of kinds of tumor cells.Ursolic acid not only can suppress the breast tumor cell growth, and can also suppress the formation of breast tumor new vessels.
Experiment material:
The strain of human breast carcinoma MCF-7 cell.
Cultural method:
Human breast cancer cell MCF-7 adopts open monolayer adherence to cultivate in the DMEM that contains 10% hyclone (a kind of culture medium that contains each seed amino acid and glucose); Condition of culture is 37 degrees centigrade; 5% carbon dioxide, saturated humidity is when treating that cell grows to 80% concentration; 0.25% trypsinization, 1 culture fluid of replacing in per 3 days.Add and tried preceding 7 days of thing and cell is changed into after with phosphate buffer (PBS) washing contain 10% and go to cultivate among the no phenol red DMEM of estrogen hyclone, to exhaust the estrogen that stores in the cell.
Thiazolyl blue (MTT) experiment:
The MCF-7 cell inoculation that in going the estrogen culture medium, cultivate 7 days is in 96 orifice plates, and cell inoculation concentration is 5 000/hole.Cultivate and treated in 12 hours to discard old culture medium behind the cell attachment, what every hole added that 200 microlitres contain that each concentration tried thing goes the estrogen culture medium.(DMSO) is solvent control group with 0.1% dimethyl sulfoxide, establishes 8 dose groups, 3 every group parallel appearance.Cultivate and add Thiazolyl blue (MTT) solution 20 microlitres/hole after 48 hours; Continue to hatch and stop after 4 hours cultivating; PBS washing 3 times, every hole adds 150 microlitre dimethyl sulfoxide, vibrates 10 minutes; Survey each hole absorbance (A) value in wavelength 490 nanometers on the enzyme-linked immunosorbent assay instrument, the result representes with each x ± s that organizes 5 hole absorbances.The survival rate of calculating MCF-7 cell under the variable concentrations effect.
Cell survival rate (%)=experimental group absorbance/normal group absorbance * 100%
Can know by Fig. 1; Medicine active ingredient of the present invention has stronger inhibitory action to the growth of human breast cancer cell MCF-7; And show certain dose-dependence, 0.1 mM/liter and 0.01 mM/when rising, the inhibitory action of pair cell is the strongest; Reach and all be higher than 90%, in 0.001 and 0.0001 lower mM/also have when rising good inhibitory effect.
Medicine according to the invention shows that through zoopery breast carcinoma is had extremely significant therapeutical effect;
Medicine of the present invention is following to the therapeutical effect zoopery of breast cancer cell MCF-7 tumor-bearing mice:
1, experiment material:
Human breast carcinoma MCF-7.Nude mice, female, body weight 20 ± 2 grams (Shandong University's animal center, laboratory animal license number SCXK Shandong 20030004).
Receive reagent thing 3
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene injection, normal saline is diluted to desired concn.
2, experimental technique:
The breast cancer cell of taking the logarithm and growing, under aseptic condition, with the fat pad of tumor cell inoculation in nude mouse left side second nipple, inoculum concentration is 1 * 10 with 1 milliliter of syringe
6/ only; Treat into (the long and short footpath of tumor is greater than 1 millimeter * 1 millimeter) begin treatment after the tumor.
To plant the tumor mice and be divided into 5 groups at random, positive group is cyclophosphamide, and blank control group and model group are normal saline, administration every day 1 time, shared 3 weeks back drug withdrawal.After treating for 4 weeks, put to death laboratory animal, complete tumor resection is measured the tumor line of apsides, and gross tumor volume adopts ab
2/ 2 formula calculate (a is a tumor body major diameter, and b is a tumor body minor axis), peel off thymus, calculate tumour inhibiting rate, thymus index.
Tumour inhibiting rate=(matched group mean tumour volume-administration group mean tumour volume)/matched group mean tumour volume * 100%
Thymus index=thymic weight/body weight * 10
Compare * P < 0.05 * * P < 0.01 and compared with normal: #P < 0.05 ##P < 0.01 with model group
Tried the growth that medicine of the present invention can suppress mice transplanted tumor, high, middle dose groups tumour inhibiting rate is respectively 60.86%, 44.34%, compares P < 0.01 or P < 0.05 with model group; The positive control cyclophosphamide can obviously suppress the growth of mouse tumor; But the mice body weight is obviously less than normal, and thymus index is obviously on the low side, and each dose groups of medicine of the present invention can not reduce mice body weight and thymus index; Medicine of the present invention is less to the normal body influence, no obvious toxic-side effects.
Experiment shows that therefore, the patient can use various pharmaceutical dosage form of the present invention in breast cancer treatment because medicine of the present invention has significant effect to treatment breast carcinoma.Medicine of the present invention can also substitute the postoperative chemotherapy phase and unite the Western medicine of use, thereby thoroughly eliminates the toxic and side effects of Western medicine.
Description of drawings
Fig. 1 is the inhibitory action curve chart of medicine active ingredient of the present invention to human breast cancer cell MCF-7.
The specific embodiment
Embodiment
Medicine of the present invention is processed medicament by medicine active ingredient and pharmaceutic adjuvant, and the structural formula of medicine active ingredient is 3
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12, the 17-diene:
Medicine active ingredient by weight percentage is that 1%-90%, pharmaceutic adjuvant are 10%-99%.Medicine of the present invention can be processed various dosage forms, as: injection: aqueous injection, freeze dried powder, tablet, capsule, granule, powder or oral liquid.
Said pharmaceutical formulation is a tablet, and the medicine active ingredient of tablet is that 20%-70%, pharmaceutic adjuvant are 30%-80%.
Said pharmaceutical formulation is a capsule, and capsular medicine active ingredient is that 20%-90%, pharmaceutic adjuvant are 10%-80%.
Said pharmaceutical formulation is aqueous injection or freeze dried powder, and the medicine active ingredient is that 1%-5%, pharmaceutic adjuvant are 95%-99%.
Said pharmaceutical formulation is powder or granule, and medicine active ingredient 10%-20%, pharmaceutic adjuvant are 80%-90%.
The method for preparing of medicine of the present invention is to adopt charred Radix Sanguisorbae to extract the medicine active ingredient earlier, is prepared into required medicament according to conventional pharmaceutical methods then, may further comprise the steps:
1. get charred Radix Sanguisorbae and pulverize the back and be medicine material, add the methanol or the ethanol of ten times of amounts of raw material, or aqueous alcohols, room temperature or be heated to 60 ℃-90 ℃ extracted 1-24 hours, repeated to extract 1-3 times, filtered, and filtrating is the concentrated fluid extract that obtains under normal pressure or decompression;
2. with step 1. in fluid extract with 5-10 times of weight aqueous dispersion, with amount of water 1/3 volumes of acetic acid ethyl ester extraction, but re-extract 5-8 time, with extract normal pressure or decompression and solvent recovery, must extractum;
3. step extractum is 2. carried out column chromatography for separation, adopt chloroform-methanol system gradient elution, the 90:10 eluting is partly merged, obtain chemical compound 3 through Sephedax-LH 20 gel filtration chromatography separation and purification again through thin layer chromatography
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12, the 17-diene;
4. get 3 by weight percentage
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 1%-90%, pharmaceutic adjuvant 10%-99%,, process medicament according to the conventional method for preparing of medicament.
Illustrate several kinds of dosage forms:
One, aqueous injection:
1. the drug effective ingredient 1%, and all the other are adjuvant
1000 milliliters
3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 10 grams, 10 milliliters of Tween 80s, sodium chloride 8 grams.
Get 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 10 grams add 10 milliliters of Tween 80s, 250 milliliters of waters for injection; Heating for dissolving filters, and adds 10% sodium carbonate acid adjustment basicity to 7.0-7.5; Add sodium chloride, add injection water to 1000 milliliter, G3 sintered filter funnel (glass) filters; Packing, embedding, 100 degrees centigrade of flowing steam sterilizations 30 minutes; Be sub-packed in 1 milliliter of ampoule bottle, every contains 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,10 milligrams of 17-diene.
2. the drug effective ingredient 2.5%, and all the other are adjuvant
3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 25 grams, 10 milliliters of Tween 80s, sodium chloride 8 grams.
Get 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 25 grams add 10 milliliters of Tween 80s, 250 milliliters of waters for injection; Heating for dissolving filters, and adds 10% sodium carbonate acid adjustment basicity to 7.0-7.5; Add sodium chloride, add injection water to 1000 milliliter, G3 sintered filter funnel (glass) filters; Packing, embedding, 100 degrees centigrade of flowing steam sterilizations 30 minutes; Be sub-packed in 1 milliliter of ampoule bottle, every contains 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,25 milligrams of 17-diene.
3. the drug effective ingredient 5%, and all the other are adjuvant
3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 50 grams, 10 milliliters of Tween 80s, sodium chloride 8 grams.
Get 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 50 grams add 10 milliliters of Tween 80s, 250 milliliters of waters for injection; Heating for dissolving filters, and adds 10% sodium carbonate acid adjustment basicity to 7.0-7.5; Add sodium chloride, add injection water to 1000 milliliter, G3 sintered filter funnel (glass) filters; Packing, embedding, 100 degrees centigrade of flowing steam sterilizations 30 minutes; Be sub-packed in 1 milliliter of ampoule bottle, every contains 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,50 milligrams of 17-diene.
Two, capsule:
1, the drug effective ingredient 20%, and all the other are adjuvant
1000
3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 40 grams, microcrystalline Cellulose 160 grams, magnesium stearate 1 gram.
Get 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene, microcrystalline Cellulose, magnesium stearate, mixing, encapsulated, every heavy 0.2 gram contains 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,40 milligrams of 17-diene.
2, the drug effective ingredient 50%, and all the other are adjuvant
1000
3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 100 grams, microcrystalline Cellulose 100 grams, magnesium stearate 1 gram.
Get 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene, microcrystalline Cellulose, magnesium stearate, mixing, encapsulated, every heavy 0.2 gram contains 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,100 milligrams of 17-diene.
3, the drug effective ingredient 70%, and all the other are adjuvant
1000
3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 140 grams, microcrystalline Cellulose 60 grams, magnesium stearate 1 gram.
Get 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene, microcrystalline Cellulose, magnesium stearate, mixing, encapsulated, every heavy 0.2 gram contains 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,140 milligrams of 17-diene.
4, the drug effective ingredient 90%, and all the other are adjuvant
1000
3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 180 grams, microcrystalline Cellulose 20 grams, magnesium stearate 1 gram.
Get 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene, microcrystalline Cellulose, magnesium stearate, mixing, encapsulated, every heavy 0.2 gram contains 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,180 milligrams of 17-diene.
Three, tablet:
1, drug effective ingredient 20%, adjuvant 80%
1000
Chemical compound 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 40 grams, starch 60 grams, dextrin 100 grams, 50% ethanol is an amount of, magnesium stearate 1 gram.
Chemical compound 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene, starch, dextrin mix, and are binding agent system wet granular with 50% ethanol; Cross 22 mesh sieves, 50 degrees centigrade of dryings 3 hours, 22 mesh sieve granulate; Add magnesium stearate mixing tabletting; Every heavy 0.2 gram contains chemical compound 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,40 milligrams of 17-diene.
2, drug effective ingredient 40%, adjuvant 60%:
1000
Chemical compound 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 80 grams, starch 40g, dextrin 80 grams, 50% ethanol is an amount of, magnesium stearate 1 gram.
Chemical compound 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene, starch, dextrin mix, and are binding agent system wet granular with 50% ethanol; Cross 22 mesh sieves, 50 degrees centigrade of dryings 3 hours, 22 mesh sieve granulate; Add magnesium stearate mixing tabletting; Every heavy 0.2 gram contains chemical compound 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,80 milligrams of 17-diene.
3, drug effective ingredient 70%, adjuvant 30%:
1000
Chemical compound 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,17-diene 140 grams, starch 20 grams, amylum pregelatinisatum 40 grams, magnesium stearate 1.5 grams.
Chemical compound 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12, the 17-diene adds starch mixing, adding distil water system soft material; No. two sieve series grains, 50 degrees centigrade of dryings 3 hours, dried granule adds amylum pregelatinisatum and magnesium stearate mix homogeneously; No. two sieve granulate, tabletting, every heavy 0.2 gram; Contain chemical compound 3 β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12,140 milligrams of 17-diene.
Claims (5)
1. a medicine of treating breast carcinoma is characterized in that: comprise that the medicine active ingredient is: 3
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12, the medicament that 17-diene and pharmaceutic adjuvant are processed, medicine active ingredient by weight percentage is that 1%-90%, pharmaceutic adjuvant are 10%-99%, 3
β-oxygen-α-L arabinofuranosyl base-28-nor-ursol-12, the structural formula of 17-diene is:
2. a kind of medicine of treating breast carcinoma according to claim 1 is characterized in that: said pharmaceutical formulation is a tablet, and the medicine active ingredient of tablet is that 20%-70%, pharmaceutic adjuvant are 30%-80%.
3. a kind of medicine of treating breast carcinoma according to claim 1 is characterized in that: said pharmaceutical formulation is a capsule, and capsular medicine active ingredient is that 20%-90%, pharmaceutic adjuvant are 10%-80%.
4. a kind of medicine of treating breast carcinoma according to claim 1 is characterized in that: said pharmaceutical formulation is aqueous injection or freeze dried powder, and the medicine active ingredient is that 1%-5%, pharmaceutic adjuvant are 95%-99%.
5. a kind of medicine of treating breast carcinoma according to claim 1 is characterized in that: said pharmaceutical formulation is powder or granule, and medicine active ingredient 10%-20%, pharmaceutic adjuvant are 80%-90%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010563758 CN102008496B (en) | 2009-12-02 | 2010-11-29 | Medicament for treating breast cancer and preparation method thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910310772 | 2009-12-02 | ||
| CN200910310772.4 | 2009-12-02 | ||
| CN 201010563758 CN102008496B (en) | 2009-12-02 | 2010-11-29 | Medicament for treating breast cancer and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102008496A CN102008496A (en) | 2011-04-13 |
| CN102008496B true CN102008496B (en) | 2012-06-06 |
Family
ID=43838959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010563758 Expired - Fee Related CN102008496B (en) | 2009-12-02 | 2010-11-29 | Medicament for treating breast cancer and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102008496B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085184A (en) * | 2007-06-18 | 2007-12-12 | 沈信堂 | Traditional Chinese medicine for treating breast cancer |
| CN101119740A (en) * | 2004-12-14 | 2008-02-06 | 成都地奥制药集团有限公司 | Use of radix sanguisorbae and its extract for preparing medicament to increase RBC and hemoglobin |
-
2010
- 2010-11-29 CN CN 201010563758 patent/CN102008496B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101119740A (en) * | 2004-12-14 | 2008-02-06 | 成都地奥制药集团有限公司 | Use of radix sanguisorbae and its extract for preparing medicament to increase RBC and hemoglobin |
| CN101085184A (en) * | 2007-06-18 | 2007-12-12 | 沈信堂 | Traditional Chinese medicine for treating breast cancer |
Non-Patent Citations (2)
| Title |
|---|
| 夏红旻，等.地榆化学成分及药理活性研究进展.《食品与药品》.2009,第11卷(第07期),全文. * |
| 王振飞,等.地榆水提液对四种癌细胞生长抑制作用的研究.《时珍国医国药》.2008,第19卷(第3期),全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102008496A (en) | 2011-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101279964B (en) | Guaiane type sesquiterpenes, preparation and medical use thereof | |
| CN101781355B (en) | Method for preparing limonin, composition and application thereof | |
| JP6389958B2 (en) | Medicinal use of anti-tumor for rutile pentacyclic triterpene saponins | |
| CN102068535A (en) | Immature bitter orange or bitter orange total flavonoids extract prepared by ethanol reflux and extraction and application thereof | |
| US20050287230A1 (en) | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof | |
| CN101428033A (en) | Mix-configuration ginsenoside Rh2 and uses thereof | |
| CN102908340B (en) | Isolicoflavonol-containing antitumor drug and application thereof | |
| CN101028322B (en) | Use of Maoliefengdou extract for preparing anti-cancer medicine | |
| CN102475698A (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| CN101880306A (en) | Stauntonia brachyanthera Hand-Mazz saponins components as well as preparation method and application thereof | |
| CN1919339B (en) | Cucurbitacin nano preparation comprising protein, preparation method and use thereof | |
| CN101948453B (en) | Novel NEO-clerodane typed diterpene compound and application thereof | |
| CN102008496B (en) | Medicament for treating breast cancer and preparation method thereof | |
| CN102688248B (en) | Use of bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors | |
| CN102357180A (en) | Traditional Chinese medicine composite for curing cancer and preparation method and application thereof | |
| CN102000099B (en) | Medicine for treating breast cancer and preparation method thereof | |
| CN106188205B (en) | A kind of purposes of momordica grosvenori alcohol derivatives monomer and combinations thereof | |
| CN101974011B (en) | New compound methyl brevicate with medical activity | |
| CN102961384A (en) | Medical application of przewaquinone A | |
| CN102000085B (en) | Medicament for treating breast cancer and preparation method thereof | |
| CN101077873B (en) | Novel NEO-clerodane type diterpene compound and application thereof | |
| CN102028698B (en) | Medicine for treating colon cancer and preparation method thereof | |
| CN101810624B (en) | Medicament for treating colon cancer and preparation method thereof | |
| CN114507265B (en) | New monoterpene glycoside compound in plant medicine Bailiangjin, and extraction and separation method and application thereof | |
| CN102432666B (en) | Novel compound separated from Actinostemma tenerum as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120606 Termination date: 20211129 |